Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

etelcalcetide

- PMLiVE

FDA will maintain the pace, vows Woodcock, but warns of skills gap

Top official unconcerned by dip in approval rate

Battling breast cancer with precision medicine (Part 2)

Dr Mark Moasser treated breast cancer survivor Laura Holmes-Haddad (interviewed in part one) with an innovative precision medicine, which at the time was yet to be approved. Here he gives...

Blue Latitude Health

Metavant/Poxel prep phase 3 for imeglimin in diabetic kidney disease

Treatment can help patients with advanced disease, companies say

- PMLiVE

New efficacy data boosts Aimovig’s migraine market lead

Data should help boost uptake

- PMLiVE

Ex-FDA chief Gottlieb’s quick move to pharma raises eyebrows

Will join Pfizer board

- PMLiVE

CHMP blocks UCB/Amgen’s Evenity approval for osteoporosis

Another obstacle for drug

Novartis day

Novartis close to US bribery settlement

Company faces huge damages pay out

- PMLiVE

Has Amgen cracked KRAS? First clinical data says maybe

Progess on cancer 'master switch'

- PMLiVE

Encouraging early data for Amgen’s BiTE therapies

Including first-in-man data from prostate cancer drug

- PMLiVE

Amgen buys Danish partner Nuevolution for $167m

Copenhagen-based biotech will remain autonomous

- PMLiVE

So far so good for Amgen’s much-anticipated KRAS inhibitor

Promise to hit previously 'undruggable' target

- PMLiVE

One hit, one miss as FDA panel votes on Daiichi’s cancer drugs

Setback for AML candidate quizartinib

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links